Venture Capital
SR One Capital Management
SR One Capital Management backs early-stage and high-growth companies, typically pre-profit, from United States. It states a focus on energy & utilities, healthcare & life sciences, media & communications and software & internet.
Stated investment criteria
What SR One Capital Management says it buys
Read from SR One Capital Management’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
| People listed on its team page | 81 |
Source
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by SR One Capital Management to consider any particular business, and nothing on this page is represented as being for sale.
SEC filings
What SR One Capital Management has raised
From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.
| Vehicles filed | 6 |
| Total capital raised | $719m |
| Largest single vehicle | $399m |
| Filing history | 2020 to 2024 |
| Smallest accepted commitment | None stated |
| Filed from | PENNSYLVANIA |
Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.
Regulatory record
How SR One Capital Management is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | SEC registered |
| Regulatory assets under management | $2.4bn |
| Employees | 28 |
| Private funds advised | 19 · $2.4bn gross |
| SEC adviser number | CRD 306361 |
Portfolio
Disclosed holdings
Companies SR One Capital Management lists on its own website. No investment years are published.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| ADARx Pharmaceuticals | — | — | — |
| ARS Pharma | — | — | — |
| Addition Therapeutics | — | — | — |
| Airnexis Therapeutics Inc | — | — | — |
| Akamis Bio | — | — | — |
| Alumis | — | — | — |
| Ancora Biotech | — | — | — |
| Antag Therapeutics ApS | — | — | — |
| Arcellx | — | — | — |
| Asceneuron | — | — | — |
| Avalyn Pharma | — | — | — |
| Avenzo Therapeutics | — | — | — |
| Bicycle Therapeutics | — | — | — |
| Biotheryx | — | — | — |
| Charm Therapeutics, Inc. | — | — | — |
| Codify Therapeutics | — | — | — |
| Corxel Pharmaceuticals Limited | — | — | — |
| Crispr Therapeutics | — | — | — |
| Crystalys Therapeutics, Inc. | — | — | — |
| Design Therapeutics | — | — | — |
| Draig Therapeutics, Ltd | — | — | — |
| Dren Bio | — | — | — |
| Econic Biosciences | — | — | — |
| Elektrofi, Inc. | — | — | — |
| Fore Biotherapeutics | — | — | — |
| HotSpot Therapeutics | — | — | — |
| Immutrin Limited | — | — | — |
| Kala Bio | — | — | — |
| Kartos Therapeutics | — | — | — |
| Mineralys Therapeutics | — | — | — |
| Mission Therapeutics | — | — | — |
| Nimbus | — | — | — |
| Nkarta Inc | — | — | — |
| Nomic | — | — | — |
| Odyssey Therapeutics | — | — | — |
| Oruka Therapeutics Inc | — | — | — |
| Palleon Pharmaceuticals | — | — | — |
| Poplar Therapeutics | — | — | — |
| Portfolio - SR | — | — | — |
| Pulmocide | — | — | — |
| Renalys | — | — | — |
| Rezo Therapeutics | — | — | — |
| River Renal | — | — | — |
| Simcha Therapeutics | — | — | — |
| Telios Pharma | — | — | — |
| Topo Therapeutics, Inc. | — | — | — |
| Tranquis Therapeutics | — | — | — |
| Veradermics, Inc. | — | — | — |
| Vibrant Biomedicines | — | — | — |
| Windward Bio | — | — | — |
| Xap Therapeutics | — | — | — |
| Zenas Biopharma | — | — | — |
Compiled from SR One Capital Management’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Energy & Utilities
What companies have actually sold for in energy & utilities, across 584 recorded transactions.
The full energy & utilities picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a energy & utilities business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this SR One Capital Management?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other venture capital investors active in energy & utilities.